Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Questions about how US President Donald Trump will shape FDA over the next four years may have driven agency staff to push out an unusually high number of guidances and regulations in recent weeks.
An end-of-administration document dump is typical as outgoing staff rush to complete projects before the new president arrives, but data...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
